Can we afford to eliminate restenosis?
- 1 February 2004
- journal article
- editorial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 43 (4), 513-518
- https://doi.org/10.1016/j.jacc.2003.11.020
Abstract
No abstract availableKeywords
Funding Information
- Boston Scientific Corporation
- Medtronic
- Cordis
This publication has 30 references indexed in Scilit:
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Drug-Eluting StentsCirculation, 2003
- Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: Results from the randomized SIRIUS trialJournal of the American College of Cardiology, 2003
- TAXUS ICirculation, 2003
- In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial)The American Journal of Cardiology, 2002
- Quality of life after balloon angioplasty or stenting for acute myocardial infarction: One-year results from the Stent-PAMI trialJournal of the American College of Cardiology, 2001
- Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel DiseaseNew England Journal of Medicine, 2001
- Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six monthsJournal of the American College of Cardiology, 1999
- Nonoperative Dilatation of Coronary-Artery StenosisNew England Journal of Medicine, 1979
- Foundations of Cost-Effectiveness Analysis for Health and Medical PracticesNew England Journal of Medicine, 1977